Tislelizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Tislelizumab (ncit:C121775)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab FDA
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab FDA